Dr. John Bridgeman, PhD.

Chief Scientific Officer

Dr. John Bridgeman is a highly accomplished immunotherapy expert with a 20 year history converting scientific ideas into tangible therapies.

With a PhD from the University of Manchester and further training at Cardiff University, John has a deep understanding of chimeric antigen receptor (CAR) biology. Over his career, John established and led the R&D team, developing novel gene engineering strategies, managing IP portfolios, and driving projects from concept to clinical execution. He has made significant strides in advancing cell-based therapies, with a proven track record in patent filings, generating novel concepts, and progressing them through to phase 1 clinical trials.

Passionate about scientific discovery, John thrives on translating research into real-world therapeutic solutions. With a strong track record in securing funding, leading teams, and fostering collaborations, John is committed to advancing T-cell therapies and shaping the future of immuno-oncology.